Executive Summary
Nine significant contract modifications totaling $1.88B signal robust U.S. government spending, with 8 bullish awards dominated by space/defense ($1.07B, 57%), infrastructure construction ($544M, 29%), and healthcare/IT ($477M, 25%). Ball Corporation gains outsized exposure via two BAE subsidiaries ($645M combined), while construction firms face firm-fixed-price risks amid long tenors (avg. 5+ years).
Unexercised options exceed $400M across deals, offering near-term upside if funded.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior Significant Contract Modifications ($10M+) digest from March 04, 2026.
Investment Signals (5)
- Ball Corp space/defense revenue locked through 2029 (HIGH)▲
Two BAE subsidiaries secure $645M obligations ($140M+$0 outlayed) from NASA/FBI, with $199M options and 19-year NASA tenor signaling stable cashflows.
- Infrastructure construction backlog builds to $544M (HIGH)▲
TEPA ($219M), Kiewit ($218M), Maymead ($107M) awards for schools, parks, highways provide 3-5 year revenue visibility, with $140M outlayed.
- Healthcare admin/IT contracts exceed $477M (MEDIUM)▲
Wisconsin Physicians ($369M, $251M outlayed to 2026) and Dell ($108M, $71M outlayed to 2027/28) lock multi-year CMS/NIH funding.
- RTX Raytheon FAA sustainment nears full obligation (HIGH)▲
$217M delivery order 98% outlayed ($206M) through 2026, with $19M options for ops sustainment.
- Minor Lockheed DEA equipment order (LOW)▲
$149k firm-fixed-price purchase with $0 outlayed, too small to materially impact.
Risk Flags (3)
- Execution [HIGH RISK]▼
Firm-fixed-price structures in $543M construction deals expose contractors to overruns/delays over 3-5 year periods.
- Execution [MEDIUM RISK]▼
$0 outlays in BAE FBI ($169M) and Lockheed ($149k) flag potential funding/execution delays.
- Market [MEDIUM RISK]▼
Long tenors (avg. 5+ years to 2029) across 7/9 contracts vulnerable to inflation/labor volatility.
Opportunities (2)
- ◆
$400M+ unexercised options (e.g., Ball $199M, Wisconsin $71M, Dell $75M) for expansion.
- ◆
Follow-on potential in BIA/NPS/FHWA construction ($544M cluster) and FAA/DOJ sustainment.
Sector Themes (3)
- ◆
29% of value ($544M) in construction for schools, parks, highways underscores IIJA-like spending continuity.
- ◆
$891M (47%) in long-term NASA/FBI/FAA awards with cost-plus structures and high outlays.
- ◆
$477M CMS/NIH commitments through 2026-2028 provide revenue visibility amid policy uncertainty.
Watch List (3)
- 👁
{"entity"=>"Ball Corporation", "reason"=>"Dual BAE hits total $645M (34% of stream), with NASA 19-year tenor and FBI BPA upside.", "trigger"=>"Q1 2026 outlays >$20M or FBI call acceleration"}
- 👁
{"entity"=>"Construction Trio (TEPA, Kiewit, Maymead)", "reason"=>"$544M FFP cluster at early stages ($140M outlayed), sensitive to execution.", "trigger"=>"Outlay acceleration to 50%+ or delay announcements"}
- 👁
{"entity"=>"RTX (Raytheon)", "reason"=>"$217M FAA near-completion offers follow-on blueprint.", "trigger"=>"$19M option exercise or new STARS DO"}
Get daily alerts with 5 investment signals, 3 risk alerts, 2 opportunities and full AI analysis of all 9 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: Significant Contract Modifications ($10M+)
🇺🇸 More from United States
View all →May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 26, 2026
US Pre-Market SEC Filings Roundup — May 26, 2026
US Pre-Market SEC Filings Roundup
May 26, 2026
Biotech Small-Cap Approvals — May 26, 2026
Biotech Small-Cap Approvals
May 26, 2026
Big Pharma Approvals — May 26, 2026
Big Pharma Approvals